» Articles » PMID: 9733503

Distinct Mechanism for Antidepressant Activity by Blockade of Central Substance P Receptors

Abstract

The localization of substance P in brain regions that coordinate stress responses and receive convergent monoaminergic innervation suggested that substance P antagonists might have psychotherapeutic properties. Like clinically used antidepressant and anxiolytic drugs, substance P antagonists suppressed isolation-induced vocalizations in guinea pigs. In a placebo-controlled trial in patients with moderate to severe major depression, robust antidepressant effects of the substance P antagonist MK-869 were consistently observed. In preclinical studies, substance P antagonists did not interact with monoamine systems in the manner seen with established antidepressant drugs. These findings suggest that substance P may play an important role in psychiatric disorders.

Citing Articles

Identifying the potential mediators of pathological complete response to neoadjuvant chemotherapy among TACR1 gene polymorphisms: a study on breast cancer patients.

Ghorbani M, Namazi S, Dehghani M, Razi F, Khalvati B, Dehshahri A Breast Cancer Res Treat. 2025; .

PMID: 40080356 DOI: 10.1007/s10549-025-07674-x.


Radiotherapy Plus the Neurokinin-1 Receptor Antagonist Aprepitant: A Potent Therapeutic Strategy for the Treatment of Diffuse Intrinsic Pontine Glioma.

Munoz M, Rosso M Cancers (Basel). 2025; 17(3).

PMID: 39941886 PMC: 11816061. DOI: 10.3390/cancers17030520.


Mediation Effect of CSF Substance P on the Association Between Smoking and Sleep.

Zhang X, Chen L, Wu Y, Chen Y, Luo X, Xu Z Brain Behav. 2025; 15(2):e70296.

PMID: 39924994 PMC: 11808183. DOI: 10.1002/brb3.70296.


Neurokinin-1 receptors in the nucleus accumbens shell influence sensitivity to social defeat stress and stress-induced alcohol consumption in male mice.

Solomon M, Nennig S, Cotton M, Whiting K, Fulenwider H, Schank J Addict Neurosci. 2025; 13.

PMID: 39801674 PMC: 11720327. DOI: 10.1016/j.addicn.2024.100174.


A scoping review of the effects of mushroom and fungus extracts in rodent models of depression and tests of antidepressant activity.

Wang C, Kim G, Aleksandrova L, Panenka W, Barr A Front Pharmacol. 2024; 15:1387158.

PMID: 38887548 PMC: 11181029. DOI: 10.3389/fphar.2024.1387158.